Gene-Chemical Interaction Annotations Click to see Annotation Detail View
Object Symbol | Species | Term | Qualifier | Evidence | With | Reference | Notes | Source | Original Reference(s) | Wdr33 | Mouse | (-)-demecolcine | decreases expression | ISO | WDR33 (Homo sapiens) | 6480464 | Demecolcine results in decreased expression of WDR33 mRNA | CTD | PMID:23649840 | Wdr33 | Mouse | (1->4)-beta-D-glucan | multiple interactions | EXP | | 6480464 | [perfluorooctane sulfonic acid co-treated with Cellulose] results in decreased expression of WDR33 mRNA | CTD | PMID:36331819 | Wdr33 | Mouse | 1,2-dimethylhydrazine | affects expression | EXP | | 6480464 | 1 and 2-Dimethylhydrazine affects the expression of WDR33 mRNA | CTD | PMID:22206623 | Wdr33 | Mouse | 2,3,7,8-tetrachlorodibenzodioxine | multiple interactions | ISO | WDR33 (Homo sapiens) | 6480464 | [Tetrachlorodibenzodioxin co-treated with 2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide] results in increased expression of WDR33 mRNA | CTD | PMID:29704546 | Wdr33 | Mouse | 2,3,7,8-tetrachlorodibenzodioxine | increases expression | ISO | Wdr33 (Rattus norvegicus) | 6480464 | Tetrachlorodibenzodioxin results in increased expression of WDR33 mRNA | CTD | PMID:34747641 | Wdr33 | Mouse | 2,4-dinitrotoluene | affects expression | ISO | Wdr33 (Rattus norvegicus) | 6480464 | 2 and 4-dinitrotoluene affects the expression of WDR33 mRNA | CTD | PMID:21346803 | Wdr33 | Mouse | 2-methylcholine | affects expression | ISO | WDR33 (Homo sapiens) | 6480464 | beta-methylcholine affects the expression of WDR33 mRNA | CTD | PMID:21179406 | Wdr33 | Mouse | 3,4-methylenedioxymethamphetamine | decreases expression | EXP | | 6480464 | N-Methyl-3 and 4-methylenedioxyamphetamine results in decreased expression of WDR33 mRNA | CTD | PMID:26251327 | Wdr33 | Mouse | 4,4'-diaminodiphenylmethane | affects expression | EXP | | 6480464 | 4 and 4'-diaminodiphenylmethane affects the expression of WDR33 mRNA | CTD | PMID:18648102 | Wdr33 | Mouse | 4,4'-sulfonyldiphenol | decreases methylation | ISO | WDR33 (Homo sapiens) | 6480464 | bisphenol S results in decreased methylation of WDR33 gene | CTD | PMID:31601247 | Wdr33 | Mouse | 5-aza-2'-deoxycytidine | affects expression | ISO | WDR33 (Homo sapiens) | 6480464 | Decitabine affects the expression of WDR33 mRNA | CTD | PMID:23300844 | Wdr33 | Mouse | aflatoxin B1 | increases methylation | ISO | WDR33 (Homo sapiens) | 6480464 | Aflatoxin B1 results in increased methylation of WDR33 gene | CTD | PMID:27153756 | Wdr33 | Mouse | antirheumatic drug | increases expression | ISO | WDR33 (Homo sapiens) | 6480464 | Antirheumatic Agents results in increased expression of WDR33 mRNA | CTD | PMID:24449571 | Wdr33 | Mouse | atrazine | increases expression | ISO | WDR33 (Homo sapiens) | 6480464 | Atrazine results in increased expression of WDR33 mRNA | CTD | PMID:22378314 | Wdr33 | Mouse | benzo[a]pyrene | affects methylation | ISO | WDR33 (Homo sapiens) | 6480464 | Benzo(a)pyrene affects the methylation of WDR33 intron and Benzo(a)pyrene affects the methylation of WDR33 promoter | CTD | PMID:27901495 and PMID:30157460 | Wdr33 | Mouse | bisphenol A | decreases expression | EXP | | 6480464 | bisphenol A results in decreased expression of WDR33 mRNA | CTD | PMID:26063408 | Wdr33 | Mouse | bisphenol A | decreases expression | ISO | WDR33 (Homo sapiens) | 6480464 | bisphenol A results in decreased expression of WDR33 mRNA | CTD | PMID:29275510 | Wdr33 | Mouse | bisphenol A | increases expression | ISO | Wdr33 (Rattus norvegicus) | 6480464 | bisphenol A results in increased expression of WDR33 mRNA | CTD | PMID:25181051 and PMID:30816183 | Wdr33 | Mouse | butanal | decreases expression | ISO | WDR33 (Homo sapiens) | 6480464 | butyraldehyde results in decreased expression of WDR33 mRNA | CTD | PMID:26079696 | Wdr33 | Mouse | caffeine | decreases phosphorylation | ISO | WDR33 (Homo sapiens) | 6480464 | Caffeine results in decreased phosphorylation of WDR33 protein | CTD | PMID:35688186 | Wdr33 | Mouse | chloroprene | increases expression | ISO | Wdr33 (Rattus norvegicus) | 6480464 | Chloroprene results in increased expression of WDR33 mRNA | CTD | PMID:23125180 | Wdr33 | Mouse | cisplatin | affects expression | ISO | WDR33 (Homo sapiens) | 6480464 | Cisplatin affects the expression of WDR33 mRNA | CTD | PMID:23300844 | Wdr33 | Mouse | cobalt dichloride | increases expression | ISO | Wdr33 (Rattus norvegicus) | 6480464 | cobaltous chloride results in increased expression of WDR33 mRNA | CTD | PMID:24386269 | Wdr33 | Mouse | copper(II) sulfate | decreases expression | ISO | WDR33 (Homo sapiens) | 6480464 | Copper Sulfate results in decreased expression of WDR33 mRNA | CTD | PMID:19549813 | Wdr33 | Mouse | crocidolite asbestos | increases expression | EXP | | 6480464 | Asbestos and Crocidolite results in increased expression of WDR33 mRNA | CTD | PMID:29279043 | Wdr33 | Mouse | diuron | increases expression | ISO | Wdr33 (Rattus norvegicus) | 6480464 | Diuron results in increased expression of WDR33 mRNA | CTD | PMID:21551480 | Wdr33 | Mouse | dorsomorphin | multiple interactions | ISO | WDR33 (Homo sapiens) | 6480464 | [NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1 and 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of WDR33 mRNA | CTD | PMID:27188386 | Wdr33 | Mouse | doxorubicin | decreases expression | ISO | WDR33 (Homo sapiens) | 6480464 | Doxorubicin results in decreased expression of WDR33 mRNA | CTD | PMID:29803840 | Wdr33 | Mouse | ethyl methanesulfonate | increases expression | ISO | WDR33 (Homo sapiens) | 6480464 | Ethyl Methanesulfonate results in increased expression of WDR33 mRNA | CTD | PMID:23649840 | Wdr33 | Mouse | folic acid | decreases expression | EXP | | 6480464 | Folic Acid results in decreased expression of WDR33 mRNA | CTD | PMID:25629700 | Wdr33 | Mouse | formaldehyde | decreases expression | ISO | WDR33 (Homo sapiens) | 6480464 | Formaldehyde results in decreased expression of WDR33 mRNA | CTD | PMID:23649840 | Wdr33 | Mouse | gentamycin | increases expression | ISO | Wdr33 (Rattus norvegicus) | 6480464 | Gentamicins results in increased expression of WDR33 mRNA | CTD | PMID:33387578 | Wdr33 | Mouse | hydrogen peroxide | affects expression | ISO | WDR33 (Homo sapiens) | 6480464 | Hydrogen Peroxide affects the expression of WDR33 mRNA | CTD | PMID:20044591 | Wdr33 | Mouse | hydrogen peroxide | decreases expression | ISO | WDR33 (Homo sapiens) | 6480464 | Hydrogen Peroxide results in decreased expression of WDR33 mRNA | CTD | PMID:18951874 | Wdr33 | Mouse | ivermectin | decreases expression | ISO | WDR33 (Homo sapiens) | 6480464 | Ivermectin results in decreased expression of WDR33 protein | CTD | PMID:32959892 | Wdr33 | Mouse | methyl methanesulfonate | increases expression | ISO | WDR33 (Homo sapiens) | 6480464 | Methyl Methanesulfonate results in increased expression of WDR33 mRNA | CTD | PMID:23649840 | Wdr33 | Mouse | methylmercury chloride | decreases expression | ISO | WDR33 (Homo sapiens) | 6480464 | methylmercuric chloride results in decreased expression of WDR33 mRNA | CTD | PMID:28001369 | Wdr33 | Mouse | nickel atom | decreases expression | ISO | WDR33 (Homo sapiens) | 6480464 | Nickel results in decreased expression of WDR33 mRNA | CTD | PMID:25583101 | Wdr33 | Mouse | ochratoxin A | decreases expression | ISO | WDR33 (Homo sapiens) | 6480464 | ochratoxin A results in decreased expression of WDR33 mRNA | CTD | PMID:22124623 | Wdr33 | Mouse | oxaliplatin | multiple interactions | ISO | Wdr33 (Rattus norvegicus) | 6480464 | [oxaliplatin co-treated with Topotecan] results in decreased expression of WDR33 mRNA | CTD | PMID:25729387 | Wdr33 | Mouse | paracetamol | increases expression | ISO | WDR33 (Homo sapiens) | 6480464 | Acetaminophen results in increased expression of WDR33 mRNA | CTD | PMID:26690555 | Wdr33 | Mouse | pentanal | decreases expression | ISO | WDR33 (Homo sapiens) | 6480464 | pentanal results in decreased expression of WDR33 mRNA | CTD | PMID:26079696 | Wdr33 | Mouse | perfluorooctane-1-sulfonic acid | multiple interactions | EXP | | 6480464 | [perfluorooctane sulfonic acid co-treated with Cellulose] results in decreased expression of WDR33 mRNA and [perfluorooctane sulfonic acid co-treated with Pectins] results in decreased expression of WDR33 mRNA | CTD | PMID:36331819 | Wdr33 | Mouse | phenobarbital | affects expression | EXP | | 6480464 | Phenobarbital affects the expression of WDR33 mRNA | CTD | PMID:19136022 | Wdr33 | Mouse | phenylmercury acetate | decreases expression | ISO | WDR33 (Homo sapiens) | 6480464 | Phenylmercuric Acetate results in decreased expression of WDR33 mRNA | CTD | PMID:26272509 | Wdr33 | Mouse | phenylmercury acetate | multiple interactions | ISO | WDR33 (Homo sapiens) | 6480464 | [NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1 and 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of WDR33 mRNA | CTD | PMID:27188386 | Wdr33 | Mouse | pirinixic acid | affects expression | EXP | | 6480464 | pirinixic acid affects the expression of WDR33 mRNA | CTD | PMID:19136022 | Wdr33 | Mouse | pirinixic acid | decreases expression | EXP | | 6480464 | pirinixic acid results in decreased expression of WDR33 mRNA | CTD | PMID:18445702 | Wdr33 | Mouse | quercitrin | decreases expression | ISO | WDR33 (Homo sapiens) | 6480464 | quercitrin results in decreased expression of WDR33 mRNA | CTD | PMID:25193878 | Wdr33 | Mouse | SB 431542 | multiple interactions | ISO | WDR33 (Homo sapiens) | 6480464 | [NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1 and 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of WDR33 mRNA | CTD | PMID:27188386 | Wdr33 | Mouse | serpentine asbestos | increases expression | ISO | WDR33 (Homo sapiens) | 6480464 | Asbestos and Serpentine results in increased expression of WDR33 mRNA | CTD | PMID:21148743 | Wdr33 | Mouse | silicon dioxide | decreases expression | ISO | WDR33 (Homo sapiens) | 6480464 | Silicon Dioxide analog results in decreased expression of WDR33 mRNA | CTD | PMID:25895662 | Wdr33 | Mouse | silicon dioxide | increases expression | ISO | WDR33 (Homo sapiens) | 6480464 | Silicon Dioxide results in increased expression of WDR33 mRNA | CTD | PMID:25351596 | Wdr33 | Mouse | sodium arsenate | increases expression | EXP | | 6480464 | sodium arsenate results in increased expression of WDR33 mRNA | CTD | PMID:21795629 | Wdr33 | Mouse | sodium arsenite | affects methylation | ISO | WDR33 (Homo sapiens) | 6480464 | sodium arsenite affects the methylation of WDR33 gene | CTD | PMID:28589171 | Wdr33 | Mouse | sodium arsenite | decreases expression | ISO | WDR33 (Homo sapiens) | 6480464 | sodium arsenite results in decreased expression of WDR33 mRNA | CTD | PMID:29301061 | Wdr33 | Mouse | Soman | decreases expression | ISO | Wdr33 (Rattus norvegicus) | 6480464 | Soman results in decreased expression of WDR33 mRNA | CTD | PMID:19281266 | Wdr33 | Mouse | titanium dioxide | decreases methylation | EXP | | 6480464 | titanium dioxide results in decreased methylation of WDR33 gene and titanium dioxide results in decreased methylation of WDR33 promoter | CTD | PMID:35295148 | Wdr33 | Mouse | topotecan | multiple interactions | ISO | Wdr33 (Rattus norvegicus) | 6480464 | [oxaliplatin co-treated with Topotecan] results in decreased expression of WDR33 mRNA | CTD | PMID:25729387 | Wdr33 | Mouse | topotecan | decreases expression | ISO | Wdr33 (Rattus norvegicus) | 6480464 | Topotecan results in decreased expression of WDR33 mRNA | CTD | PMID:25729387 | Wdr33 | Mouse | trichostatin A | decreases expression | ISO | WDR33 (Homo sapiens) | 6480464 | trichostatin A results in decreased expression of WDR33 mRNA | CTD | PMID:24935251 | Wdr33 | Mouse | troglitazone | decreases expression | EXP | | 6480464 | troglitazone results in decreased expression of WDR33 mRNA | CTD | PMID:28973697 | Wdr33 | Mouse | ursodeoxycholic acid | affects expression | ISO | WDR33 (Homo sapiens) | 6480464 | Ursodeoxycholic Acid affects the expression of WDR33 mRNA | CTD | PMID:18422935 | Wdr33 | Mouse | valdecoxib | decreases expression | ISO | Wdr33 (Rattus norvegicus) | 6480464 | valdecoxib results in decreased expression of WDR33 mRNA | CTD | PMID:24136188 | Wdr33 | Mouse | valproic acid | decreases methylation | ISO | WDR33 (Homo sapiens) | 6480464 | Valproic Acid results in decreased methylation of WDR33 gene | CTD | PMID:29154799 | Wdr33 | Mouse | valproic acid | decreases expression | ISO | WDR33 (Homo sapiens) | 6480464 | Valproic Acid results in decreased expression of WDR33 mRNA | CTD | PMID:23179753 more ... | Wdr33 | Mouse | valproic acid | decreases expression | EXP | | 6480464 | Valproic Acid results in decreased expression of WDR33 mRNA | CTD | PMID:21427059 | Wdr33 | Mouse | vinclozolin | decreases expression | ISO | Wdr33 (Rattus norvegicus) | 6480464 | vinclozolin results in decreased expression of WDR33 mRNA | CTD | PMID:23034163 | Wdr33 | Mouse | vinclozolin | increases methylation | ISO | Wdr33 (Rattus norvegicus) | 6480464 | vinclozolin results in increased methylation of WDR33 gene | CTD | PMID:31682807 | Wdr33 | Mouse | vincristine | decreases expression | ISO | WDR33 (Homo sapiens) | 6480464 | Vincristine results in decreased expression of WDR33 mRNA | CTD | PMID:23649840 | |